Screening for ATTR Amyloidosis Speakers


Workshop Moderator:
Frederick L. Ruberg, MD
Boston University School of Medicine and Boston Medical Center

Frederick L. Ruberg, MD is an Associate Professor of Medicine and Radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC), specializing in cardiac imaging and infiltrative heart disease. He attended the University of Pennsylvania School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center. Dr. Ruberg has an active clinical practice as the senior cardiologist in the BU/BMC Amyloidosis Center. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Associate Director of the Cardiovascular Medicine Fellowship program, director of the cardiac MRI program at BMC as well as the Integrated Pilot Grants Program of the Boston University Clinical and Translational Science Institute.

Dr. Ruberg is also Senior Associate Editor of Circulation: Cardiovascular Imaging and a Fellow of the American Heart Association and American College of Cardiology. His NIH and industry funded research program applies non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. Current projects involve the application of pyrophosphate imaging for detection of ATTR amyloidosis, application of echocardiographic strain imaging as a disease marker in AL amyloidosis, evaluation of treatments of ATTR amyloidosis, and validation of point of care diagnostic tools for cardiac amyloidosis identification in the outpatient clinic. Dr. Ruberg is committed to raising awareness of cardiac amyloidosis among clinicians and the general population so as to afford early diagnosis and enhanced access to disease modifying therapies.

Marianna Fontana, MD
University College London Hospitals, London

Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, where she is deputy head of Center and deputy clinical lead. She obtained her Medical degree (MD) and qualifications as a cardiologist at the University of Pisa. She was appointed Director of the UCL CMR unit at the RFH in 2015 and Professor of Cardiology in 2020. She was appointed deputy Head of Center for Amyloidosis and Acute Phase Proteins and deputy clinical lead of the National Amyloidosis Center in 2019. She was awarded with an intermediate fellowship from the British Heart Foundation in 2018. Her research interests include CMR wih multiparametric mapping and pathogenesis, diagnosis and treatment of cardiac amyloidosis.

Mathew S. Maurer, MD
Columbia University

Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYork Presbyterian Hospital. Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus. 

Dr. Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship.  He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha.  He completed training in internal medicine and cardiology at NewYork Presbyterian Hospital and was Chief Medical Resident. 

He has published over 290 articles including peer reviewed manuscripts, reviews and book chapters. He was chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults. 


Yukio Ando, MD, PhD
Department of Amyloidosis Research, Nagasaki International University

Yukio Ando, MD, PhD is the President and a Professor of Department of Amyloidosis,  of Nagasaki International University.  He is also a Professor Emeritus, Graduate School, Kumamoto University. He is the past President of International Society of Amyloidosis (ISA) and now the President of Japan Society of Amyloidosis (JSA).  

Dr. Ando attended the University of Kumamoto School of Medicine, and completed internal medicine training at Kumamoto University Hospital, where he earned his PhD.  He spent two years at Arao City Hospital near Kumamoto, where there is a concentration of ATTRv V30Met patients. In addition,  he studied two years at the University of Umea in Sweden, where a large number of ATTRv patients live.  With Professor Ole Suhr, several diagnostic methods and therapies for ATTRv patients were proposed during his stay at the University.  During his Kumamoto University days, he was Professor in the Department of Laboratory Medicine and the Department of Neurology. As Dean, he organized the Graduate School of Medical Sciences and established the Amyloidosis Center at Kumamoto University Hospital where he found several novel amyloidoses and new mutations of the ATTR gene which lead to the development of ATTRv amyloidosis.  Current projects involve the developing rapid and simple new diagnostic methods for amyloidosis and therapies for ATTR.  He continues to investigate the mechanism of amyloid formation.  A unique antibody therapy for ATTRv which he originally developed is now in Phase II clinical trials in the USA in collaboration with pharmaceutical companies.

Mitsuharu Ueda, MD, PhD
Department of Neurology, Kumamoto University
Amyloidosis Center at Kumamoto University Hospital

Mitsuharu Ueda, MD, PhD is a Professor of Department of Neurology, Kumamoto University, and the Director of Amyloidosis Center at Kumamoto University Hospital, Kumamoto, Japan.

Dr. Ueda graduated with his medical degree from the Kumamoto University School of Medicine, Kumamoto, Japan, in 1999. He completed his residencies in the Department of Neurology at Kumamoto University Hospital, Kumamoto, Japan. He spent one year at Arao City Hospital near Kumamoto, where there is a concentration of ATTRv V30Met patients. He earned his PhD at Kumamoto University. He became Assistant Professor in the Department of Diagnostic Medicine at the Kumamoto University Graduate School of Medical Sciences, and was a Visiting Research Fellow in the Department of Pathology and Laboratory Medicine at Indiana University-Purdue University, Indianapolis, IN, USA, before returning as Associate Professor. He became Professor of Neurology at Kumamoto University and Director of Amyloidosis Center at Kumamoto University Hospital in 2020.

Dr. Ueda’s research interests include the pathogenesis of ATTR Amyloidosis, animal and cell models for amyloidosis, and molecular diagnosis of genetic disorders.